Target Market Motilent operates in the medical imaging AI space focused on quantitative GI biomarkers using MRI post-processing. Potential sales opportunities include NHS trusts and research institutions seeking cost-effective, safer biomarkers to support GI disorder trials and clinical decision-making.

Public Funding Recent NIHR funding and UK government-backed investment indicate strong interest in GIQuant deployments within the NHS and related projects. A sales angle is to align with funded programs and co-financing opportunities to accelerate adoption.

Growth Momentum Evidence of continued funding rounds and partnerships (including with IBD Relief) suggests increasing credibility and market traction. Target expansion into broader digestive disease cohorts and multi-site studies to scale adoption.

Tech Backbone Cloud-first tech stack (AWS, Azure, Docker, MongoDB) and collaboration tooling (Jira, Confluence) enable scalable software deployments. Upsell possibilities include enterprise-grade deployment, data governance, and security features for larger healthcare networks.

Strategic Partners Existing collaborations with research bodies and government-backed programs create joint go-to-market avenues. Engage with partners for co-sell opportunities, pilot programs, and NHS trust-wide rollouts to accelerate market penetration.